Eli Lilly and Company announced on April 10 it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.
Nicole Verbeeck is Founder and Editor-in-Chief of Moonshot for Life, covering global health progress. She is also founder of Juneau Cayenne, a creative design, content and technology lab crafting innovative storytelling experiences for clients in healthcare and life sciences worldwide and she is a healthy food chef focusing on prevention of disease.
Become a Moonshot for Life Insider
Join the Moonshot for Life community to access exclusive content, receive email updates, be part of specialized communities, chat with experts, participate in giveaways, and more.
Our Top 3 in Healthcare
Ending Infectious Diseases
6 Health Experts Weighed in on COVID-19 During ‘One World: Together At Home’
Nicole VerbeeckApril 19, 2020